Stagnant treatment future seen for inherited orphan blood diseases

Generally unimpressive treatment line-ups combined with weak product pipelines will lead to modest growth for several inherited orphan blood disease markets, states business intelligence provider GBI Research.

According to the firm’s new report, the global therapeutic markets for sickle cell anemia, thalassemia and hereditary angioedema (HAE) are all expected to exhibit uninspired growth. The greatest value increase is expected from the sickle cell anemia market, which is forecast to climb at a compound annual growth rate (CAGR) of 9%, from $36 million in 2012 to $70 million in 2019. Meanwhile, the global HAE therapeutics market is predicted to increase at a miserly CAGR of 3% during the same period, from $1.5 billion to $1.9 billion.

Kimberley Carter, associate analyst at GBI Research states: “Even though orphan blood disorders are rare, the three diseases featured in this report are hereditary and have a large impact on the lives of the families and ethnic groups afflicted by these diseases. Many of these diseases cause debilitating health issues and limit lifespan. Because of this there is a great need for curative and disease modifying therapies. While this may require significant R&D investment, any drugs that are successful in treating these diseases can be expected to be priced at the highest premium range.”